



Xellia Pharmaceuticals appoints John Stewart as Senior Vice President of Global Product Supply

Copenhagen, Denmark, 18 January 2023 - Xellia Pharmaceuticals ('Xellia'), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies has appointed John Stewart as Senior Vice President of Global Product Supply from 1 January 2023.

John returns to Xellia from LEO Pharma where he was Vice President of Biologics & External Manufacturing. From 2009 to 2013 John was Xellia's Copenhagen Site Leader. In total he has over 25 years of pharmaceutical experience at organizations such as GSK, Ascendis Pharma, Centrient Pharmaceuticals and most recently LEO Pharma.

John will be part of Xellia's leadership team and will be based at the Company's headquarters in Copenhagen, Denmark. He will bring with him and leverage his extensive experience in managing multi-site manufacturing networks and external manufacturing partners in both Active Pharmaceutical Ingredient and Aseptic Drug Product manufacturing technologies.

Carl-Åke Carlsson, CEO and President at Xellia Pharmaceuticals, commented:

"We welcome John back to the Xellia team. He brings a strong track record in managing pharmaceutical manufacturing and his experience in anti-infective production will be invaluable."

John graduated as a Chemical Engineer from the University of Paisley in the UK and will be based at the Group's Copenhagen headquarters.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO
+45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris
+44 (0) 20 7457 2020
xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company and a global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. Xellia has an extensive history in developing, manufacturing, and commercializing anti-

infective products, including Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms, where the majority are injectable drug products.

As an organization, Xellia is committed to providing security and consistency of supply of critical care therapies. Through a global vertically integrated supply chain, the Company continuously works to improve supply security through multiple sources of in-house production of its APIs and drug products, and in conjunction through working alongside Xellia's R&D centers of excellence. Through innovation and with the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia Pharmaceuticals is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,800 people.